Defining information fractions in group sequential clinical trials with multiple endpoints
Tu Xu, Qin Qin, Xin Wang
Contemporary Clinical Trials Communications · 2018
doi:10.1016/j.conctc.2018.03.005 (opens in a new tab)
We email you when a new notice or a question about this paper appears.
Abstract
The group sequential design has been well understood and widely applied in designs of late phase clinical trial to enable potentially early stopping for efficacy or futility. The information fraction (IF) is one of the key elements to determine the decision boundary at the interim analyses. The family-wise error rate (FWER) control is highly critical for clinical trials with multiple endpoints to be tested. In this article, we illustrate the importance of properly defining the information fraction for each individual endpoint regarding the FWER control through the numerical evaluation and a case study.
Abstract licence: CC BY-NC-ND
References10
10 more references, whose wording the paper’s licence keeps private.
Reads
Read by people on this page
None yet.
Checked or read by AI through naulon
None yet.
A person counts once a day per paper. We keep no cookie and no address: a reader is a hash that changes every day. Any month under five reads shows no number.
Are you an author?
Is this your paper?
Claim it to add your note and be paid when agents cite it. Free.